Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
3.110
-0.110 (-3.42%)
At close: Nov 13, 2026, 4:00 PM EST
2.900
-0.210 (-6.75%)
Pre-market: Nov 16, 2026, 4:56 AM EST

Company Description

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.

It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.

The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.

It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide.

The company was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd.
Entera Bio logo
CountryIsrael
Founded2010
IPO DateJun 28, 2018
IndustryBiotechnology
SectorHealthcare
Employees27
CEOMiranda Toledano

Contact Details

Address:
Kiryat Hadassah Minrav Building, 5th Floor
Jerusalem, 9112002
Israel
Phone972 2 532 7151
Websiteenterabio.com

Stock Details

Ticker SymbolENTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001638097
CUSIP NumberM40527109
ISIN NumberIL0011429839
SIC Code2836

Key Executives

NamePosition
Miranda J. Toledano M.B.A.Chief Executive Officer and Director
Dr. Hillel Galitzer M.B.A., Ph.D.Chief Operating Officer
Dr. Gregory Burshtein Ph.D.Chief of Research and Development
Dana Yaacov-Garbeli CPAChief Financial Officer
Dr. Rachel B. WagmanChief Clinical Advisor
Cherin SmithExecutive Vice President and Head of Clinical Operations
Dr. Constantin Itin Ph.D., R.Ph.Head of Biopharmaceutics and Bioanalytics
Michele McDermottMD and Executive Vice President of Medical Affairs
Riccardo Paolo Camisasca M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Nov 13, 2026SCHEDULE 13GFiling
Nov 6, 202610-QQuarterly Report
Nov 6, 20268-KCurrent Report
Oct 30, 2026SCHEDULE 13GFiling
Oct 27, 20268-KCurrent Report
Oct 14, 2026DEF 14AOther definitive proxy statements
Oct 6, 20268-KCurrent Report
Sep 23, 2026PRE 14AOther preliminary proxy statements
Aug 28, 2026EFFECTNotice of Effectiveness
Aug 28, 2026424B3Prospectus